Replacement Notice. See Section 4.11.
Replacement Notice. See ss.5.11.
Replacement Notice. See §6.14.
Replacement Notice. See Section 5.12. SANIFILL. Sanifill, Inc., a Delaware corporation having its chief executive office at 0000 Xxxxxx Xxxxxx, Suite 4000, Houston, Texas 77002. SANIFILL CONVERTIBLE SUBORDINATED DEBT. Indebtedness under that certain indenture dated as of March 1, 1996, by and between Sanifill and Chase Bank of Texas (f/k/a Texas Commerce Bank National Association) as Trustee, as in effect on August 7, 1997, with respect to $115,000,000 of 5% convertible subordinated debt due March 1, 2006.
Replacement Notice. If GSK intends to exercise its Replacement Right, GSK shall send a written replacement request to CureVac (at any time before the expiry of the period specified in Section 3.6.1) identifying: (i) the Product to be replaced ("Replaced Product"); (ii) the Replacement Product that GSK seeks to Develop; (iii) the LNP or CVCM that GSK desires to use for the Replacement Product; and (iv) if applicable, the Antibody and/or Antigens that GSK wishes to clear in accordance with Section 3.4 and Section 3.5 ("Replacement Request"). Within [*****] following the Replacement Request, the Parties will hold a JSC meeting for discussing the details with respect to the Replacement Product and the desired LNP or CVCM for such Replacement Product, and CureVac will provide to GSK all data, documents and information reasonably required by GSK to assess whether it wishes to exercise its Replacement Right with respect to the respective Replacement Product, including the amount of the Replacement Exercise Fee, if any. Within [*****] following this JSC and unless directed otherwise by GSK in writing, the Antigen/Antibody List Rep will perform the requisite Antigen/Antibody clearance in accordance with Section 3.4 and, if applicable, Section 3.5.1, GSK shall exercise its Replacement Right by sending written notice to CureVac within [*****] following the confirmation by the Antigen/Antibody List Rep that the Antibodies and/or Antigens are available to GSK ("Replacement Notice"). Following receipt of the Replacement Notice by CureVac, the Parties shall as soon as reasonable practicable work on an initial R&D Plan for the Replacement Product in accordance with Section 4.3.2, and CureVac shall, if an LNP is selected by GSK and cleared, secure the LNP License from the respective LNP Provider.
Replacement Notice. See §4.11. Reserve Rate. The rate, expressed as a decimal, at which the Banks would be required to maintain reserves under Regulation D of the Board of Governors of the Federal Reserve System (or any subsequent or similar regulation relating to such reserve requirements) against “Eurocurrency Liabilities” (as such term is defined in Regulation D), or against any other category of liabilities which might be incurred by the Banks to fund Loans bearing interest based on the Eurodollar Rate, if such liabilities were outstanding.
Replacement Notice. See Section 5.12. -14-
Replacement Notice. See Section 2.22.
Replacement Notice. See Section 5.12.Sanifill. Sanifill, Inc., a Delaware corporation having its chief executive office at 1001 Xxxxxx Xxxxxx, First City Tower, Suite 4000, Housxxx, Xxxxx 00000. Sanifill Merger. The merger of Sanifill and Quatro Acquisition Corp., a Subsidiary of the Borrower, pursuant to the terms of the Sanifill Merger Agreement.
Replacement Notice. See Section 6.11. Revolving Credit Loans. Collectively, the Syndicated Loans, the Swing Line Loans and the Competitive Bid Loans. Revolving Credit Maturity Date. June 28, 2002. Revolving Credit Notes. Collectively, the Competitive Bid Notes, the Syndicated Notes and the Swing Line Note.
